KRSA
Korsana Biosciences, Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$34.99
+3.77%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +74.0%
- EBITDA
- +74.0%
- EPS
- +71.3%
Three-year CAGR
- Revenue
- +91.1%
- EBITDA
- -15.4%
- EBIT
- -37.1%
- Net income
- -15.4%
- EPS
- +9.9%
- Free cash flow
- +23.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026